Our Mission
Puma Biotechnology is a biopharmaceutical company dedicated to the acquisition, development, and commercialization of novel therapeutics for the treatment of cancer.
News Releases
Year
News Releases
- Dec. 12, 2014 - Puma Biotechnology Announces Positive Interim PB272 (Neratinib) Phase II Data at 2014 CtrC-AACR San Antonio Breast Cancer Symposium Read
- Dec. 2, 2014 - Puma Biotechnology Updates Timeline for Filing New Drug Application -NDA Filing Currently Anticipated for Q1 2016 Read
- Nov. 13, 2014 - Puma Biotechnology Announces Positive Top Line Results from PB272 Phase II trial in HER2 Positive Metastatic Breast Cancer (NEfERTT trial) Read
- Nov. 12, 2014 - Puma Biotechnology to Present at Stifel 2014 Healthcare Conference Read
- Nov. 10, 2014 - Puma Biotechnology Reports Third Quarter 2014 Financial Results Read
- Sept. 29, 2014 - Puma Biotechnology Announces Positive Initial Results from PB272 Phase II trial in HER2 Mutated Non-Small Cell Lung Cancer Read
- Sept. 3, 2014 - Puma Biotechnology Announces Late-Breaking Oral Presentation on Neratinib in NSCLC with HER2 Mutations at ESMO 2014 Read
- Aug. 11, 2014 - Puma Biotechnology Reports Second Quarter 2014 Financial Results Read
- July 22, 2014 - Puma Biotechnology Announces Positive Top Line Results from Phase III PB272 trial in Adjuvant Breast Cancer (ExteNET trial) Read
- July 22, 2014 - Puma Biotechnology Announces Amendment to Neratinib Licensing Agreement with Pfizer Read
- June 5, 2014 - Puma Biotechnology to Present at the Goldman Sachs 35th Annual Global Healthcare Conference Read
- June 1, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data at the 2014 ASCO Annual Meeting Read
- May 29, 2014 - Puma Biotechnology to Present at Jefferies 2014 Global Healthcare Conference Read
- May 15, 2014 - Puma Biotechnology to Present at UBS Global Healthcare Conference Read
- May 14, 2014 - Puma Biotechnology Expands Cohort in Phase II trial of PB272 (Neratinib) in HER2 Mutation-Positive Solid Tumor Patients Read
- May 12, 2014 - Puma Biotechnology Reports First Quarter 2014 Financial Results Read
- May 7, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch 2014 Health Care Conference Read
- April 7, 2014 - Puma Biotechnology Announces Presentation of Positive PB272 Phase II Data from I-SPY 2 TRIAL Read
- March 12, 2014 - Puma Biotechnology to Present at Bank of America Merrill Lynch Smid Cap Conference Read
- March 5, 2014 - Puma Biotechnology Announces Oral Presentation on I-SPY2 trIAL at AACR Annual Meeting 2014 Read
- March 3, 2014 - Puma Biotechnology Reports Fourth Quarter and Full Year 2013 Financial Results Read
- Feb. 25, 2014 - Puma Biotechnology to Present at Cowen Health Care Conference Read
- Feb. 14, 2014 - Puma Biotechnology Closes $138 Million Public Offering of Common Stock Read
- Feb. 12, 2014 - Puma Biotechnology Announces Underwriters' Full Exercise of Option to Purchase Additional Shares Read
- Feb. 11, 2014 - Puma Biotechnology Prices Public Offering of Common Stock Read
- Feb. 6, 2014 - Puma Biotechnology Announces Positive Outcome of European Opposition Proceedings Read